MPCC Annual Symposium

Symposium videos & presentations — click here.

Symposium Photos — click here.

The 17th Annual Massachusetts Prostate Cancer Symposium — leading prostate cancer specialists provide up-to-date information on the latest in prostate cancer treatment and research — in user-friendly language!

17th Annual Massachusetts Prostate Cancer Symposium

Friday, May 16, 2014 - 7:30 AM – 2:00 PM

Marriott Newton — 2345 Commonwealth Avenue Newton,  MA 02466

OPEN TO THE PUBLIC AT NO CHARGE

   2014_brochure-header

A PRE-SYMPOSIUM SESSION FOR MEDICAL PROFESSIONALS

AGENDA

7:30 AM Pre-symposium session for medical professionals
8:45 AM Greetings
2014_brochure-Mark_KennedyMark Kennedy
Executive Director,
Massachusetts Prostate Cancer Coalition
9:00 AM Opening Keynote
10:15 AM Concurrent Educational Sessions I
11:30 AM Concurrent Educational Sessions II
12:45 PM Presentation of the Charles Austin Award
Luncheon

SPONSORS

Many thanks to this year’s generous sponsors.

  • Massachusetts Department of Public Health
  • Massachusetts Prostate Cancer Coalition
  • Peter and Connie Lacaillade
  • Garth and Lindsay Greimann
  • Beth Israel Deaconess Medical Center
  • Dana-Farber Cancer Institute
  • Brigham and Women’s Hospital
  • John Carberry
  • Patricia and Hall Swaim
  • Institute of Urology, Lahey Clinic
  • Barron Center for Men’s Health at Mount Auburn Hospital 

EDUCATIONAL GRANTS

The 17th Annual Symposium is supported, in part, by educational grants from:

Millennium Pharmaceuticals
AbbVie, Inc.
Genentech, Inc.

 2014_brochure-Peter_Chang

Peter Chang, MD
Beth Israel Deaconess Medical Center


An Update for Primary Care Physicians:
Using patient-reported outcomes to enable patient- centered prostate cancer care

Every practitioner who provides care to patients with prostate cancer appreciates the impact of patients’ quality-of-life concerns, both during treatment decision-making and while suffering from treatment- related side effects. Until recently, however, it was not realistically feasible to use patient reported outcomes (PRO) instruments to objectively assess quality of life in the clinical setting. New developments now allow linkage of the research and clinical realms, and enable practitioners to make prostate cancer care more individualized and patient-centered.
OPENING KEYNOTE
 2014_brochure-Eric_Klein Eric Klein, MD
Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic

Choosing the Right Patient for Active Surveillance: How active surveillance is changing the management of prostate cancer

Many men diagnosed with prostate cancer can be watched safely, often for many years. This talk will give an overview of new ways to measure tumor aggressiveness to help with patient selection for active surveillance, and which patients are most likely to do well.

 

 EDUCATIONAL SESSIONS

10:15 AM – 11:15 AM
(Concurrent Educational Sessions I)
11:30 AM – 12:30 PM
(Concurrent Educational Sessions II)
A Conversation with Dr. Klein
An opportunity for an in-depth follow-up conversation with Dr. Klein based on the key elements of his keynote presentation.
Eric Klein, MD
Cleveland Clinic

Can Men with Prostate Cancer Ever Receive Testosterone Therapy?
For 70 years it was believed that higher levels of testosterone caused prostate cancer and made it grow more rapidly. For this reason, testos- terone therapy was prohibited in men with prostate cancer. A new understanding of the relationship between testosterone and prostate cancer has allowed some exploration of testosterone use in selected men with prostate cancer. Dr. Morgentaler will share his research in this area and discuss who may benefit from testosterone therapy.
Abraham Morgentaler, MD
Men’s Health Boston
Beth Israel Deaconess Medical Center

Contemporary Management of Advanced Prostate CancerThis session will focus on the latest thinking, treatment and management of advanced disease, including an update on clinical trials underway for prostate cancer.
Rick Lee, MD
Massachusetts General Hospital

Genetic Research: Developments in prostate cancerGenetic research in prostate cancer continues to evolve. This session will highlight how genetics is creating new ways to match treatments to tumors more effectively.
Eliezer Van Allen, MD
Dana-Farber/Harvard Cancer Center 

Outreach to High-Risk Communities
A review of what information should be conveyed to men considered to be at high risk for prostate cancer mortality due to age and/or family history. Key developments and activities that are impacting screening and diagnosis for men at high risk will be discussed.
Anita Christie
Massachusetts Department of Public Health
Mark Kennedy

MPCC
Dalton Skerritt

Center for the Elimination of Health and Social Inequities and Disparities (CEHSID)

Consensus on PSA Testing for African American Men
Prostate cancer screening is one of the most controversial areas of management in modern medicine today. However, men at high risk for prostate cancer are often times not included in the debate. African Amer- ican men suffer the highest mortality rate from prostate cancer, which is the largest racial disparity for any type of major cancer. The Prostate Health Education Network (PHEN) issued a Consensus Statement on PSA Testing, signed by 26 leading prostate cancer experts, to provide clear guidance for men deemed to be at high risk for prostate cancer. This session will present and examine the PHEN Consensus Statement.
Thomas Farrington
PHEN

Navigating the Medical Experience: Best practices
Navigating the medical experience after being diagnosed with prostate cancer can be daunting—especially if you don’t ask the right questions at the start. Join this panel of medical professionals and prostate cancer survivors as they provide insight on how to get what you need after diagnosis.
Rupal Bhatt, MD
BIDMC
Mark Kennedy
MPCC
A.J. Brown, Jr.
Prostate cancer survivor

Prostate Cancer and the Psyche
Prostate cancer exerts psychological impacts on both men and their family members. This session will review the stressors associated with diagnosis, treatment, complications and uncertainty about progression before considering the ways that men typically manage, and the place of psychological interventions.
John Peteet, MD
Brigham and Woman’s Hospital

Treatment Options for Men Who Recur After Radiation
In this session, radiation oncologist Dr. Paul Nguyen will describe possible treatment paths for men with prostate cancer whose disease recurs after prior radiation.
Paul Nguyen, MD
Brigham and Women’s Hospital

Imaging of Prostate Cancer: Creating your strategic plan
Existing treatments for prostate cancer have advantages and disadvantages, and imaging can provide key information to help create a personalized treatment plan. Join Drs. Sun and Bubley to learn how new developments in imaging are advancing diagnosis and treatment of prostate cancer.
Maryellen Sun, MD
BIDMC
Glenn Bubley, MD

BIDMC

PRESENTATION OF THE CHARLES AUSTIN AWARD

The Charles Austin Award was established by the Massachusetts Prostate Cancer Coalition in 2006 to honor an outstanding member of its board of directors, Charles Austin. Mr. Austin, himself a prostate cancer survivor, has worked tirelessly to raise awareness of the risks of prostate cancer, particularly in the African-American community, and of the benefit of early detection and treatment options.

2014 Charles Austin Award Presented to William Tinney

Past recipients:
2011: Manny Hamelburg
2010: Thomas L. Farmer
2007: William R. Whitmore
2006: Charles Austin